Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
about
The impact of surgery and mild hyperthermia on tumor response and angioneogenesis of malignant melanoma in a rat perfusion modelNifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusion.TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusionsIsolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicityLack of efficacy of Doxil in TNF-alpha-based isolated limb perfusion in sarcoma-bearing rats.Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery.Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma.20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose mattersEffects of hypoxia on human cancer cell line chemosensitivity.Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability.
P2860
Q24805237-35D4BD30-0778-4FBE-A730-BF784F778534Q30871587-3269DCAB-D0CD-42B4-BC9F-0A9AC8C1BE07Q33180038-A59D5D43-E764-419B-89A1-2DB6C33398F0Q33181229-237158BC-B0CF-4336-BFDB-59E334E91DFCQ33181472-3E7C5B90-1688-437C-B94F-2CA4E1EC1A97Q33183585-92E3B4B0-E06B-4237-AAFA-C5739C8BE1DAQ33204006-44DD63A8-0240-43DC-B5A6-07A7D2FF8394Q33263624-12F7E00D-F97D-48A4-8CAD-8DA936FDCFEDQ33309291-DD316D1A-0F3F-4018-A83B-8AA4B82D67B5Q34006197-F27E917F-7FC5-4F91-8E6E-C1180684F2EBQ34799788-22E0ACA8-66CA-499F-818F-B0A4AD0C628EQ38372151-F04D1C96-64AE-45D5-A869-489641DB98CF
P2860
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats.
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Prerequisites for effective is ...... r alpha and melphalan in rats.
@ast
Prerequisites for effective is ...... r alpha and melphalan in rats.
@en
type
label
Prerequisites for effective is ...... r alpha and melphalan in rats.
@ast
Prerequisites for effective is ...... r alpha and melphalan in rats.
@en
prefLabel
Prerequisites for effective is ...... r alpha and melphalan in rats.
@ast
Prerequisites for effective is ...... r alpha and melphalan in rats.
@en
P2093
P2860
P356
P1476
Prerequisites for effective is ...... r alpha and melphalan in rats.
@en
P2093
A M Eggermont
E R Manusama
J H de Wilt
M G van Ijken
S T van Tiel
T L ten Hagen
P2860
P304
P356
10.1038/SJ.BJC.6990335
P407
P577
1999-04-01T00:00:00Z